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cess and makes an attempt to establish an alternative
procedural endpoint (3). Thus, it provides the long
awaited proof that the scar inhomogeneity should be
the essential target for ablation.
However, we have the feeling that both endocar-
dial and epicardial ablation of all abnormal signals
could be more beneﬁcial even though the studied
cohort consisted of patients with ischemic heart dis-
ease. Unfortunately, epicardial ablation was per-
formed only in a minority of the patients in the
substrate-based ablation group. The possible beneﬁt
of combined endocardial and epicardial ablation of
abnormal signals should be investigated in future
trials. On the other side, even though the overall
procedure duration between both groups was com-
parable, the mean radiofrequency time was expect-
edly longer in the substrate-ablation group, which
raises concerns about myocardial stunning, ﬂuid
overload, and hemodynamic deterioration that can
blunt the beneﬁts of an achieved electrical stability.
Our biggest concern is the deﬁnition for “abnormal
potentials” that gathers under the same roof local
abnormal ventricular activities, double, split, late, and
fragmented potentials, which certainly do not bear the
same clinical relevance. We are worried that a nonse-
lective ablation of all abnormal potentials such as the
split but high-amplitude signals in the border zone
may be associated with collateral damage due to
expansion of necrosis to the adjacent viable myocar-
dium. Therefore, we would like to appeal for a careful
and contemplative implementation of this strategy in
the clinical routine until more data about the safety of
the scar homogenization appear.*Julia Anna Lurz, MD
Arash Arya, MD
Gerhard Hindricks, MD
Borislav Dinov, MD
*Department of Electrophysiology
University of Leipzig – Heart Center
Struempelstrasse 39
04289 Leipzig
Germany
E-mail: julia.koch@me.com
http://dx.doi.org/10.1016/j.jacc.2016.03.606
Please note: Dr. Hindricks has received research grants from St. Jude Medical
and Boston Scientiﬁc. The other authors have reported that they have no re-
lationships relevant to the contents of this paper to disclose.
RE F E RENCE S
1. Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of Stable VTs Versus Sub-
strate Ablation in Ischemic Cardiomyopathy. J Am Coll Cardiol 2015;66:2872–82.
2. Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogeni-
zation of the scar versus limited substrate ablation for the treatment ofelectrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol
2012;60:132–41.
3. Dinov B, Arya A, Schratter A, Schirripa V, et al. Catheter ablation of ven-
tricular tachycardia and mortality in patients with nonischemic dilated car-
diomyopathy: can noninducibility after ablation be a predictor for reduced
mortality? Circ Arrhythm Electrophysiol 2015;8:598–605.REPLY: A Prima Vista Ablation
of Ventricular Tachycardia
Should We Abandon the Mapping of VT?We read with interest the letter by Dr. Lurz and
colleagues in regards to the VISTA (Ablation of
Clinical Ventricular Tachycardia Versus Addition of
Substrate Ablation on the Long Term Success Rate
of VT Ablation) trial (1). Surviving myoﬁbers within
the scar tissue represent the most known arrhyth-
mogenic substrate of post-infarction ventricular
tachycardias (VT) (2). The identiﬁcation of these
myocytes and myoﬁbers is achieved by three-
dimensional voltage systems via a mapping cath-
eter that identiﬁes abnormal electrograms within
the scar (3). Whether this can be better achieved in
VT or in sinus rhythm has been one of the hypoth-
eses generating the VISTA trial (1). Most VTs are not
well tolerated by the patients requiring ablation in
sinus rhythm. Lurz and colleagues are concerned
about a possible damage to the heart performance
with extensive scar “homogenization.” However, as
reported in the trial (1), we observed a trend toward
improvement in left ventricular ejection fraction
and New York Heart Association functional class at
1-year follow-up in the substrate-based group. Left
ventricular ejection fraction improvement from
baseline was higher in the substrate group (2.4 
6.6% vs. 2.1  5.8%, respectively; p ¼ 0.13) as well
as the New York Heart Association functional class
improvement (1). “Scar homogeneization” achieve
better freedom from VT at follow-up. We did not
observe myocardial stunning or ﬂuid overload.
Therefore, the authors’ concerns about extensive
ablation in the scar are without clinical evidence.
We also disagree about their concern on the deﬁni-
tion of “abnormal potentials.” This is well charac-
terized in the literature and there is nothing
“magic” about it (3,4). In addition, high amplitude
delayed and complex electrograms can be found in
the border zone. In this respect, most of the present
series on ischemic cardiomyopathy, including one
from the Leipzig group (5), concentrate their lesions
along the scar border.
In regards to the need of endo-epicardial homo-
geneization of the scar, we would like to clarify that
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671the 2012 paper excluded patients with coronary artery
bypass graft (CABG) and showed that the need of
epicardial ablation in patients without CABG
appeared higher than previously reported. In the
randomized trial, patients with CABG were included
and the possibility of epicardial ablation was lower.
To conclude, although we consider the authors’
appeal of interest, we would like to reinforce the
concept that no data in regards to their concern are
available and that the VISTA randomized trial con-
ﬁrms the validity of substrate-based ablation as a
better way to perform ischemic VT ablation. We
can certainly say that the present one is safe and
efﬁcacious and therefore valid not only “A PRIMA
VISTA.”Luigi Di Biase, MD, PhD
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